Skip to main content

Advertisement

SpringerLink
Log in

Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

An Erratum to this article was published on 18 January 2013

Abstract

Background

The present study aimed to clarify the beneficial effect of allopurinol on cardiovascular morbidity and mortality in a cohort of hypertensive nephropathy patients with impaired kidney function.

Methods

One hundred and seventy-eight patients diagnosed with hypertensive nephropathy and presenting with impaired kidney function (estimated glomerular filtration rate <45 mL/min/1.73 m2) were recruited from nephrology clinics. Oral allopurinol was prescribed in 67 of these patients. The effects of allopurinol use on the development of cardiovascular disease (i.e. ischemic heart disease, congestive heart failure, and stroke) and all-cause death was analyzed using the Cox proportional hazard model.

Results

During the follow-up of 18.4 months (mean), 28 primary events occurred. Basal use of allopurinol was a significant beneficial factor (hazard ratio = 0.342, p = 0.0434, standard error = 0.53058) after adjusting for confounding factors.

Conclusion

The use of allopurinol in hypertensive subjects with impaired kidney function appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality, indicating that this xanthine oxidase inhibitor protects the vascular system, at least in this specific group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  PubMed  CAS  Google Scholar 

  2. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.

    Article  PubMed  Google Scholar 

  3. Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.

    Article  PubMed  Google Scholar 

  4. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–8.

    Article  PubMed  CAS  Google Scholar 

  5. Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol. 2010;14:333–9.

    Article  PubMed  Google Scholar 

  6. Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, et al. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Hypertens Res. 2011;34:1106–10.

    Article  PubMed  Google Scholar 

  7. Noman A, Ang DSC, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet. 2010;375:2161–7.

    Article  PubMed  CAS  Google Scholar 

  8. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.

    Article  PubMed  CAS  Google Scholar 

  9. National Institue of Neurological Disorders and Stroke Ad Hoc Committee. Classification of cerebrovascular disease. Stroke. 1990;21:637–76.

    Article  Google Scholar 

  10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  PubMed  CAS  Google Scholar 

  11. Takahashi M, Fukuda Y, Iwata S. Fundamental evaluation and efficacy for protein to creatinine ratio by ATLAS kit cartridge PRO12 using automatic urine analyzer Clinitek ATLAS XL. Igaku To Yakugaku 2002; 48:727–735 (in Japanese).

    Google Scholar 

  12. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.

    Article  PubMed  CAS  Google Scholar 

  13. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988–93.

    Article  PubMed  CAS  Google Scholar 

  14. Terawaki H, Takada Y, Era S, Funakoshi Y, Nakayama K, Nakayama M, et al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial. 2010;14:465–71.

    Article  PubMed  Google Scholar 

  15. Terawaki H, Matsuyama Y, Matsuo N, Ogura M, Mitome J, Hamaguchi A, et al. A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients. Clin Exp Nephrol. 2012. doi:10.1007/s10157-012-0610-x.

  16. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2:556–62.

    Article  PubMed  CAS  Google Scholar 

  17. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503–7.

    Article  PubMed  CAS  Google Scholar 

  18. Hozawa A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 2006; 187:401–407.

    Google Scholar 

  19. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–96.

    Article  PubMed  CAS  Google Scholar 

  20. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.

    Article  PubMed  Google Scholar 

  21. Simmonds HA, Cameron JS, Morris GS, Davies PM. Allopurinol in renal failure and the tumour lysis syndrome. Clin Chim Acta. 1986;160:189–95.

    Article  PubMed  CAS  Google Scholar 

  22. Kenneth R, Noone RM, Stone WJ. Severe allopurinol toxicity. Am J Med. 1984;76:47–56.

    Google Scholar 

  23. Terawaki H, Suzuki T, Yoshimura K, Hasegawa T, Takase H, Nemoto T, et al. A case of allopurinol-induced muscular damage in a chronic renal failure patient. Nihon Jinzo Gakkai Shi. 2002; 44:50–53 (in Japanese).

    Google Scholar 

  24. Saji M. A study of serum oxipurinol concentration and renal function in patients administered allopurinol. Nihon Jinzo Gakkai Shi 1996; 38:640–650 (in Japanese).

    Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant from Astellas Pharm Inc. The authors express their special thanks to Ms. Makiko Nakayama for her assistance.

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Fukushima Medical University School of Medicine, Fukushima, Japan

    Hiroyuki Terawaki & Masaaki Nakayama

  2. Center for Advanced Integrated Renal Science, Tohoku University Graduate School of Medicine, Sendai, Japan

    Masaaki Nakayama, Masato Matsushima, Mariko Miyazaki, Hiroshi Sato, Toshinobu Sato & Sadayoshi Ito

  3. Department of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

    Emiko Miyazawa, Yaeko Murata, Keisuke Nakayama, Mariko Miyazaki & Sadayoshi Ito

  4. Department of Clinical Research, The Jikei University School of Medicine, Tokyo, Japan

    Masato Matsushima

  5. Department of Clinical Pharmacology, Tohoku University Graduate School of Pharmacology, Sendai, Japan

    Hiroshi Sato

  6. Kidney Center, Sendai-shakaihoken Hospital, Sendai, Japan

    Mitsuhiro Sato, Toshinobu Sato & Yoshio Taguma

Authors
  1. Hiroyuki Terawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emiko Miyazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaeko Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keisuke Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masato Matsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mariko Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mitsuhiro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshinobu Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshio Taguma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sadayoshi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Terawaki.

About this article

Cite this article

Terawaki, H., Nakayama, M., Miyazawa, E. et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clin Exp Nephrol 17, 549–553 (2013). https://doi.org/10.1007/s10157-012-0742-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0742-z

Keywords

Search

Navigation